NCT05660954 2025-09-05
CABOTHYROID
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT03611595 2025-08-28
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
University of California, San Diego
Phase 1 Recruiting
NCT03299946 2024-09-03
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT05289856 2024-03-07
Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)
Johannes Gutenberg University Mainz
Phase 2 Active not recruiting
NCT03542877 2022-07-15
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
University of Colorado, Denver
Phase 2 Completed
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT01663272 2018-09-19
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT01428219 2017-12-12
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
University of Michigan Rogel Cancer Center
Phase 2 Terminated